Envestnet Asset Management Inc. raised its holdings in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 16.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 58,548 shares of the biotechnology company’s stock after buying an additional 8,327 shares during the period. Envestnet Asset Management Inc. owned 0.13% of United Therapeutics worth $16,282,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of United Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company’s stock worth $923,703,000 after purchasing an additional 163,542 shares during the last quarter. BlackRock Inc. increased its stake in shares of United Therapeutics by 0.3% during the 3rd quarter. BlackRock Inc. now owns 4,327,368 shares of the biotechnology company’s stock worth $906,061,000 after purchasing an additional 13,196 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after purchasing an additional 710,668 shares during the last quarter. State Street Corp increased its stake in shares of United Therapeutics by 7.2% during the 1st quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock worth $291,809,000 after purchasing an additional 109,226 shares during the last quarter. Finally, Farallon Capital Management LLC increased its stake in shares of United Therapeutics by 40.0% during the 3rd quarter. Farallon Capital Management LLC now owns 549,673 shares of the biotechnology company’s stock worth $115,091,000 after purchasing an additional 156,977 shares during the last quarter. 95.63% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages recently commented on UTHR. Morgan Stanley decreased their price target on shares of United Therapeutics from $320.00 to $316.00 and set an “overweight” rating on the stock in a research note on Monday, April 10th. UBS Group decreased their price target on shares of United Therapeutics from $330.00 to $310.00 and set a “buy” rating on the stock in a research note on Monday, April 10th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $265.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 23rd. LADENBURG THALM/SH SH decreased their price target on shares of United Therapeutics from $285.00 to $256.00 in a research note on Thursday, May 4th. Finally, Argus decreased their price target on shares of United Therapeutics from $300.00 to $280.00 and set a “buy” rating on the stock in a research note on Friday, April 21st. Two analysts have rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $285.82.
United Therapeutics Price Performance
United Therapeutics (NASDAQ:UTHR – Get Rating) last released its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported $4.86 EPS for the quarter, beating analysts’ consensus estimates of $4.26 by $0.60. United Therapeutics had a net margin of 36.76% and a return on equity of 15.49%. The company had revenue of $506.90 million during the quarter, compared to analyst estimates of $514.37 million. During the same period last year, the business earned $5.03 earnings per share. United Therapeutics’s revenue was up 9.7% compared to the same quarter last year. Equities analysts expect that United Therapeutics Co. will post 18.09 EPS for the current year.
Insider Buying and Selling at United Therapeutics
In other news, CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 8th. The shares were sold at an average price of $253.38, for a total value of $2,027,040.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $32,939.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 8,000 shares of United Therapeutics stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $253.38, for a total value of $2,027,040.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $32,939.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $7,846,459.61. The disclosure for this sale can be found here. Insiders sold a total of 224,379 shares of company stock worth $51,658,957 over the last three months. 12.40% of the stock is owned by insiders.
United Therapeutics Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Read More
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are BuyingÂ
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
